Category: 301335-39-7

Claffey, Michelle M. published the artcileApplication of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors, Recommanded Product: 3-Phenoxyazetidine hydrochloride, the publication is Journal of Medicinal Chemistry (2012), 55(21), 9055-9068, database is CAplus and MEDLINE.

Phosphodiesterase 9A inhibitors have shown activity in preclin. models of cognition with potential application as novel therapies for treating Alzheimer’s disease. Our clin. candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochem. properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clin. trials, we sought to identify a preclin. candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chem. strategies of structure-based design with parallel chem., a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclin. candidate 19 that demonstrated free brain/free plasma â‰? in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.

Journal of Medicinal Chemistry published new progress about 301335-39-7. 301335-39-7 belongs to ethers-buliding-blocks, auxiliary class Azetidine,Salt,Benzene,Ether, name is 3-Phenoxyazetidine hydrochloride, and the molecular formula is C9H12ClNO, Recommanded Product: 3-Phenoxyazetidine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Claffey, Michelle M. published the artcileApplication of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors, Recommanded Product: 3-Phenoxyazetidine hydrochloride, the main research area is structure preparation phosphodiesterase 9A inhibitor brain penetration Alzheimer’s t.

Phosphodiesterase 9A inhibitors have shown activity in preclin. models of cognition with potential application as novel therapies for treating Alzheimer’s disease. Our clin. candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochem. properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clin. trials, we sought to identify a preclin. candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chem. strategies of structure-based design with parallel chem., a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclin. candidate 19 that demonstrated free brain/free plasma ≥1 in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.

Journal of Medicinal Chemistry published new progress about Alzheimer disease. 301335-39-7 belongs to class ethers-buliding-blocks, name is 3-Phenoxyazetidine hydrochloride, and the molecular formula is C9H12ClNO, Recommanded Product: 3-Phenoxyazetidine hydrochloride.

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Yang, Minjian published the artcileDesign, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton’s tyrosine kinase (BTK) inhibitors, Safety of 3-Phenoxyazetidine hydrochloride, the main research area is pyrrolopyrimidine preparation Brutons tyrosine kinase mol docking antitumor activity; B-Cell lymphomas; BTK inhibitor; Kinase selectivity.

Here, four key regions where inhibitors bind to BTK were identified by analyzing the existing crystal structures of BTK complexes. Then, a scaffold-based mol. design work flow was established by integrating fragment-growing method, deep learning-based framework XGraphBoost and mol. docking, leading to four compounds that showed potency against BTK. Optimization of compounds I and II led to the discovery of the potent BTK inhibitor compound III by using in vitro potency and pharmacokinetic (PK) studies to prioritize the compounds Compound III exhibited great BTK inhibition activity (IC50 = 0.7 nM) along with high oral absorption. Moreover, compound III demonstrated excellent kinase selectivity, especially over EGFR kinase, and low toxicity. In a TMD8 xenograft model, compound III significantly inhibited tumor growth (TGI = 104%) at a dosage of 50 mg/kg, indicating its potential as a novel therapeutic option for B-cell lymphomas.

European Journal of Medicinal Chemistry published new progress about Anilines Role: RCT (Reactant), RACT (Reactant or Reagent). 301335-39-7 belongs to class ethers-buliding-blocks, name is 3-Phenoxyazetidine hydrochloride, and the molecular formula is C9H12ClNO, Safety of 3-Phenoxyazetidine hydrochloride.

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Yang, Minjian published the artcileDesign, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton’s tyrosine kinase (BTK) inhibitors, Safety of 3-Phenoxyazetidine hydrochloride, the main research area is pyrrolopyrimidine preparation Brutons tyrosine kinase mol docking antitumor activity; B-Cell lymphomas; BTK inhibitor; Kinase selectivity.

Here, four key regions where inhibitors bind to BTK were identified by analyzing the existing crystal structures of BTK complexes. Then, a scaffold-based mol. design work flow was established by integrating fragment-growing method, deep learning-based framework XGraphBoost and mol. docking, leading to four compounds that showed potency against BTK. Optimization of compounds I and II led to the discovery of the potent BTK inhibitor compound III by using in vitro potency and pharmacokinetic (PK) studies to prioritize the compounds Compound III exhibited great BTK inhibition activity (IC50 = 0.7 nM) along with high oral absorption. Moreover, compound III demonstrated excellent kinase selectivity, especially over EGFR kinase, and low toxicity. In a TMD8 xenograft model, compound III significantly inhibited tumor growth (TGI = 104%) at a dosage of 50 mg/kg, indicating its potential as a novel therapeutic option for B-cell lymphomas.

European Journal of Medicinal Chemistry published new progress about Anilines Role: RCT (Reactant), RACT (Reactant or Reagent). 301335-39-7 belongs to class ethers-buliding-blocks, name is 3-Phenoxyazetidine hydrochloride, and the molecular formula is C9H12ClNO, Safety of 3-Phenoxyazetidine hydrochloride.

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem